#transgene $TNG broke MA200#transgene $TNG broke MA200, closed on high volume. Could see a violent move into 1.75 and then above 2.00
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.227 EUR
−22.33 M EUR
1.18 M EUR
34.63 M
About TRANSGENE
Sector
Industry
CEO
Alessandro Riva
Website
Headquarters
Strasbourg
Founded
1979
ISIN
FR0005175080
FIGI
BBG000BPCWG0
Transgene SA is a biotechnology company that focuses on designing and developing targeted immunotherapies for the treatment of cancer. Its products include TG4001, TG4050, TG6002, BT-001 & TG6050. The company was founded in December 1979 and is headquartered in Strasbourg, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of TNG is 0.782 EUR — it has increased by 0.26% in the past 24 hours. Watch TRANSGENE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange TRANSGENE stocks are traded under the ticker TNG.
TNG stock has fallen by −10.57% compared to the previous week, the month change is a −22.51% fall, over the last year TRANSGENE has showed a −46.07% decrease.
We've gathered analysts' opinions on TRANSGENE future price: according to them, TNG price has a max estimate of 4.00 EUR and a min estimate of 2.20 EUR. Watch TNG chart and read a more detailed TRANSGENE stock forecast: see what analysts think of TRANSGENE and suggest that you do with its stocks.
TNG stock is 2.31% volatile and has beta coefficient of 0.98. Track TRANSGENE stock price on the chart and check out the list of the most volatile stocks — is TRANSGENE there?
Today TRANSGENE has the market capitalization of 102.66 M, it has decreased by −5.58% over the last week.
Yes, you can track TRANSGENE financials in yearly and quarterly reports right on TradingView.
TRANSGENE is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
TNG net income for the last half-year is −16.48 M EUR, while the previous report showed −6.43 M EUR of net income which accounts for −156.54% change. Track more TRANSGENE financial stats to get the full picture.
No, TNG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 158.00 employees. See our rating of the largest employees — is TRANSGENE on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TRANSGENE EBITDA is −36.17 M EUR, and current EBITDA margin is −2.86 K%. See more stats in TRANSGENE financial statements.
Like other stocks, TNG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TRANSGENE stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TRANSGENE technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TRANSGENE stock shows the strong sell signal. See more of TRANSGENE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.